Diagnostic Accuracy of Doppler Ultrasound and Role of Uterine Artery Doppler

NCT ID: NCT03530475

Last Updated: 2018-05-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-22

Study Completion Date

2018-08-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will be conducted on (100) pregnant women diagnosed as placenta previa by ultrasonography and are candidates for either emergency or elective repeated cesarean section or hysterectomy (if the diagnosis of placenta accreta is confirmed).

All of those patients are presenting during the period of may 2018 to july 2018 to Kasr-Al Ainy Obstetrics outpatient clinic or casualty department during their 3rd trimester.

All of them will be assorted according to certain inclusion and exclusion criterions as follow:

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be conducted on (100) pregnant women diagnosed as placenta previa by ultrasonography and are candidates for either emergency or elective repeated cesarean section or hysterectomy (if the diagnosis of placenta accreta is confirmed).

Those patients are attending to Kasr-Al Ainy Obstetrics outpatient clinic or casualty department during their 3rd trimester.

Ultrasound and doppler will be done to all patients to diagnose placenta accreta . The diagnosis will be confirmed by intraoperative assessments and histopathological examination of the uterus after cesarean hysterectomy

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Placenta Accreta

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

placenta previa

cases diagnosed as placenta previa diagnosed by ultrasound and doppler

Group Type ACTIVE_COMPARATOR

ultrasound and doppler

Intervention Type DIAGNOSTIC_TEST

• Ultrasound examination (2D gray scale and color doppler )

1\. Confirming the presence of placenta previa 2,To assess the possibility of concomitant placenta accreta (Sonographic findings that have been associated with placenta accreta (1) Loss of normal hypoechoic retroplacental zone (2) Multiple vascular lacunae (irregular vascular spaces) within placenta, (3) Blood vessels or placental tissue bridging uterine-placental margin, myometrial-bladder interface, or crossing uterine serosa1 (4) Retroplacental myometrial thickness of 1 mm (5) Bladder wall interruption (6) Presence of placental bulge (7) Utero-vesical hypervascularity (8) presence of lacunae feeder vessels.

3\. Assessment of uterine artery Doppler in different cases of placenta previa.

. Documentation of the operative findings during cesarean section and/or cesarean hysterectomy procedures.

Histopathological examination of the hysterectomy specimens to assess the degree of myometrial invasion.

placenta accreta

placenta previa diagnosed as placenta accreta by ultrasound and doppler

Group Type ACTIVE_COMPARATOR

ultrasound and doppler

Intervention Type DIAGNOSTIC_TEST

• Ultrasound examination (2D gray scale and color doppler )

1\. Confirming the presence of placenta previa 2,To assess the possibility of concomitant placenta accreta (Sonographic findings that have been associated with placenta accreta (1) Loss of normal hypoechoic retroplacental zone (2) Multiple vascular lacunae (irregular vascular spaces) within placenta, (3) Blood vessels or placental tissue bridging uterine-placental margin, myometrial-bladder interface, or crossing uterine serosa1 (4) Retroplacental myometrial thickness of 1 mm (5) Bladder wall interruption (6) Presence of placental bulge (7) Utero-vesical hypervascularity (8) presence of lacunae feeder vessels.

3\. Assessment of uterine artery Doppler in different cases of placenta previa.

. Documentation of the operative findings during cesarean section and/or cesarean hysterectomy procedures.

Histopathological examination of the hysterectomy specimens to assess the degree of myometrial invasion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ultrasound and doppler

• Ultrasound examination (2D gray scale and color doppler )

1\. Confirming the presence of placenta previa 2,To assess the possibility of concomitant placenta accreta (Sonographic findings that have been associated with placenta accreta (1) Loss of normal hypoechoic retroplacental zone (2) Multiple vascular lacunae (irregular vascular spaces) within placenta, (3) Blood vessels or placental tissue bridging uterine-placental margin, myometrial-bladder interface, or crossing uterine serosa1 (4) Retroplacental myometrial thickness of 1 mm (5) Bladder wall interruption (6) Presence of placental bulge (7) Utero-vesical hypervascularity (8) presence of lacunae feeder vessels.

3\. Assessment of uterine artery Doppler in different cases of placenta previa.

. Documentation of the operative findings during cesarean section and/or cesarean hysterectomy procedures.

Histopathological examination of the hysterectomy specimens to assess the degree of myometrial invasion.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Gestational age more than 28 weeks
* Single living fetus.
* One or more cesarean section or hysterotomy.
* Placenta previa (all grades) with high possibility of morbidly adherent placenta accreta (all types).

Exclusion Criteria

* Maternal chronic medical disorder (diabetes mellitus or hypertension).
* Pregnancy induced disorders (pre-eclampsia or gestational diabetes).
* Associated fetal anomalies.
Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kasr El Aini Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

hala nabil

principle investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hala Nabil, M.D

Role: PRINCIPAL_INVESTIGATOR

Cairo University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hala Nabil, M.D

Role: CONTACT

02001002412549

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

5000

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.